Country intelligence
Deals, market moves, science and policy across the platform tagged to Switzerland.
Medical legal since 2011 and home to Europe's most extensive adult-use trials, with full legalisation now drafting.
Market sizing, forecasts, pricing and patient data are available to Prohibition Partners subscribers. View on Prohibition Partners →
In August 2022 Switzerland reclassified medical cannabis from a prohibited to a controlled narcotic, bringing it under the same framework as other narcotic medicines and establishing Swissmedic-licensed cultivation, trade and dispensation.
Any licensed doctor can prescribe, most commonly for severe chronic or neuropathic pain, MS spasticity, cancer-related pain and chemotherapy-related nausea.
Compulsory insurance (OKP) generally does not cover medical cannabis, with case-by-case exceptions in hardship cases; private insurers may cover it on an individual basis.
Unusually, the Swiss market is dominated by extracts, and most products used in treatment are cultivated and processed domestically.
Switzerland began adult-use pilot trials in 2023 and now runs seven, letting participants legally buy cannabis for scientific study; a legislative committee gave preliminary approval in 2025 to draft a full legalisation bill that could create Europe's first commercial adult-use market.
The trials — including Weed Care in Basel, Züri Can in Zurich, Grashaus, Cann-L, La Cannabinothèque, SCRIPT and Cannabis Research Zürich — study how regulated sales affect consumption, health, youth protection and the illicit market. Early interim results report orderly operation, diversion of sales away from the illicit market and no rise in consumption.
A February 2025 draft bill would let adults grow, buy, possess and consume cannabis under a state-monopoly retail model with THC-based taxation; if passed, the law is expected around 2026.
